Stocktoria
TG THERAPEUTICS, INC. TGTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1995-12-14
TG THERAPEUTICS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 20.0% | 12.7% | 8.8% | -7839.0% | -5154.3% |
| Net margin | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% |
| FCF margin | -4.1% | -12.3% | -13.4% | -6326.2% | -4425.7% |
| Return on assets | 42.1% | 4.0% | 3.8% | -115.6% | -91.7% |
| Return on equity | 69.0% | 10.5% | 7.9% | -382.0% | -146.8% |
| Debt / equity | 0.38× | 1.10× | 0.63× | 1.21× | 0.29× |
| Current ratio | 4.10 | 6.25 | 5.92 | 3.16 | 5.06 |
| Revenue growth | 87.3% | 40.8% | 8290.0% | -58.4% | 4300.7% |
Source: SEC EDGAR filings · CIK 0001001316 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.